Tokyo, Aug. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062354) titled 'Evaluation of Extended Ustekinumab Dosing Intervals for Remission Maintenance in Refractory Ulcerative Colitis' on Aug. 1.
Study Type:
Interventional
Study Design:
Basic Design - Parallel
Randomization - Non-randomized
Blinding - Open -no one is blinded
Control - Active
Primary Sponsor:
Institute - Osaka Medical and Pharmaceutical University
Condition:
Condition - Ulcerative Colitis
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - Ustekinumab (UST) is a monoclonal antibody targeting the p40 subunit shared by interleukin (IL)-12 and IL-23. Following induction therap...